State of Play: BIO Coffee Chat Covers How State Policies Impact Access

Why It Matters

State‑level policies determine coverage, pricing and reimbursement for life‑saving therapies, directly affecting patient outcomes and industry revenue streams.

Key Takeaways

• CMS directive forces Medicare Advantage plans to cover FDA‑approved ALS drug.
• Prescription Drug Affordability Boards face criticism for limiting Medicaid and patient access.
• Washington passed 340B transparency law; Minnesota reported $1.34 billion 340B revenue.
• 24 states enacted laws expanding insurance coverage for biomarker testing.
• Proposed federal defrayal rule could curb state‑mandated benefits like biomarker coverage.

Pulse Analysis

The United States’ fragmented health system gives state legislatures outsized influence over how innovative medicines reach patients. As BIO’s senior patient‑advocacy leaders noted, states act as ‘laboratories of democracy,’ testing policies that later cascade to the federal level. A recent win illustrates this dynamic: after a concerted campaign, the ALS Association persuaded the Centers for Medicare & Medicaid Services to issue a directive prohibiting Medicare Advantage plans from denying coverage of an FDA‑approved, accelerated‑approval ALS drug on the grounds that it is ‘experimental.’ This unprecedented move not only restores access for a genetically defined patient cohort but also sets a precedent for how state‑driven advocacy can reshape national payer behavior.

Parallel to coverage battles, state drug‑pricing initiatives are stirring controversy. Prescription Drug Affordability Boards (PDABs), now under consideration in Colorado, Virginia, Louisiana and Illinois, aim to cap prices but risk disrupting Medicaid reimbursement and supply chains, according to BIO’s VP of State Government Relations. Meanwhile, Washington’s new 340B transparency law and Minnesota’s disclosure of $1.34 billion in 340B revenue underscore growing scrutiny of hospital‑level discounts that often bypass patients. Stakeholders warn that without careful design, such measures can erode Medicaid funding and create unintended access barriers, prompting industry groups to lobby for carve‑outs and financial assessments.

Access to precision medicine is another frontier where state action matters. Twenty‑four states have enacted statutes mandating insurance coverage of biomarker testing, a critical step toward matching patients with targeted cancer therapies. However, a proposed federal ‘defrayal’ rule threatens to penalize states that fund benefits beyond the ACA’s essential health benefits, potentially rolling back recent gains in biomarker coverage and other supplemental services. Advocates stress the importance of patient storytelling, coalition building, and focused lobbying to protect these advances. By aligning resources across states and maintaining pressure on both state and federal regulators, the biotech community can safeguard and expand patient access to breakthrough treatments.